Atemtherapien zur Behandlung von Atemnot bei Patienten mit fortgeschrittenen Erkrankungen, ein systematischer Review nach Cochrane Methodik
Reduzierte Artikel in dieser Kategorie
| Verlag | Cuvillier |
| Auflage | 2022 |
| Seiten | 210 |
| Format | 21 x 14,8 x 1,2 cm |
| Gewicht | 279 g |
| ISBN-10 | 3736976224 |
| ISBN-13 | 9783736976221 |
| Bestell-Nr | 73697622A |
Background: Dyspnoea is a very common and distressing symptom in advanced disease which is still difficult to manage. Since standard-pharmacological treatment was not sufficient enough to release the symptoms entirely, supplementary nonpharmacological interventions were used increasingly.
Objectives: To assess the effects and safety of interventions targeting respiration as the predominant underlying mechanism of effect to relieve breathlessness in adults suffering from advanced disease.
Methods: 44 randomised controlled trials, including 1658 participants with advanced disease were incorporated in this review. The screening and data extraction were conducted independently by two researchers each throughout the review process. Different groups of non-pharmacological respiratory therapies (e.g. respiratory muscle training (RMT), breathing training (BT), fan or chest wall vibration) were analysed. Comparators were divided into active (AC) or incactive controls (IAC). All outcome measurements focusing on the relief of breathlessness were extracted and reported.
Results: Evaluated studies showed that respiratory therapies, especially RMT, had positive influences in reducing dyspnoea and are more effective than inactive comparators. No effects on secondary outcomes (e.g. performance (6-MWT) or respiratory parameters (FEV1), quality of life, or depression and anxiety) could be shown. The total dropout numbers in intervention and control groups were similar. None of the reported adverse events were related to any of the interventions. Consequently, respiratory therapies seemed to be safe.
Conclusion: The overall quality of evidence across all pooled analyses was low, but respiratory therapies could be considered safe and trends towards effectiveness were shown.
